Abbott Laboratories $ABT Shares Sold by Toth Financial Advisory Corp

Toth Financial Advisory Corp reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 18.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 92,196 shares of the healthcare product maker’s stock after selling 20,574 shares during the period. Toth Financial Advisory Corp’s holdings in Abbott Laboratories were worth $8,366,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ABT. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the fourth quarter worth approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.4%

Shares of ABT stock opened at $111.37 on Friday. The stock has a fifty day moving average of $97.27 and a two-hundred day moving average of $99.75. The firm has a market capitalization of $192.71 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ABT shares. Leerink Partners dropped their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Stifel Nicolaus lowered their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Robert W. Baird initiated coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.67.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wolfe Research upgraded Abbott Laboratories (ABT) from “peer perform” to “outperform” and set a $130 target, implying substantial upside from recent trading levels. Benzinga analyst upgrade report
• Positive Sentiment: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market growth, broad branded-generic offerings and resilient healthcare demand. Expanding biosimilar opportunities could provide an additional long-term growth avenue. Zacks EPD growth report
• Positive Sentiment: Abbott and Google Health announced a multiyear partnership to integrate Abbott’s Lingo continuous glucose-monitoring data into Google’s AI-powered consumer health tools. The collaboration could increase Lingo’s visibility, support personalized metabolic-health services and generate valuable real-world data. Abbott and Google Health Lingo partnership
• Positive Sentiment: Bank of America Securities issued a “buy” recommendation for ABT, reinforcing the constructive Wall Street view. Bank of America buy rating
• Neutral Sentiment: Abbott’s stock outperformed competitors during a strong broader trading session, reflecting market momentum but not a new company-specific fundamental catalyst. MarketWatch trading report
• Neutral Sentiment: Abbott’s PULSE study is evaluating earlier treatment for atrial fibrillation. Positive clinical results could expand future device demand, but the study remains ongoing and carries execution and clinical risk. TipRanks PULSE study report
• Neutral Sentiment: Abbott renewed its blood-donation campaign with the Big Ten amid a U.S. blood shortage. The initiative supports Abbott’s brand and blood-management business, though its direct near-term financial impact is likely limited. Abbott and Big Ten blood donation campaign

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.